Risk-AI brings Hedge Fund Portfolio Analysis to iPad(R) NEW

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Risk-AI brings Hedge Fund Portfolio Analysis to iPad(R)

NEW YORK, N.Y., Jan. 20, 2015 (GLOBE NEWSWIRE) -- via PRWEB - Investors, consultants and hedge fund managers are now able to conduct sophisticated risk analysis, construct and optimize portfolios and generate reports on hedge funds' performance and risk via a native iOS Risk-AI Fusion® app.

Risk-AI Fusion® is the first ever, practical software for risk analysis of hedge funds for iPad®. The application provides users with a rich set of tools previously available only on desktop or web-based platforms.

"This version of Fusion App brings Portfolio Analysis and Construction features to iPad®, making Fusion the first fully functional risk management App on iPad®. Investors can now analyze their current portfolios and potential changes to allocations. In fact, Risk-AI Fusion® is not really an App, but a full blown Risk Management Application" said Aleksey Matiychenko, Senior Partner & CEO of Risk-AI, LLC.

Risk-AI Fusion® is available free of charge to all users, however, certain premium features require nominal monthly subscription fees.

Common scenarios of using the App include:

1. Investment consultants reviewing client portfolios to recommend changes by using our proprietary Portfolio Fit Report®.

2. Research Analysts analyzing hedge fund information at networking events or investment / capital introduction conferences (hedge fund data can be entered on the fly.

3. Research Analysts using performance and risk analysis for questions during investment due diligence meetings.

4. Client development analysts creating and exporting custom reports for meetings with potential or current investors.

Risk-AI works with several major hedge fund data providers and can enable App users' access to their hedge fund data subscriptions via the App.

For more information on Risk-AI Fusion® please visit http://www.Risk-AI.com

To download the free App please follow this link: https://itunes.apple.com/us/app/risk-ai-fusio...?ls=1&mt=8

Notice: iPad® is a registered trademark of Apple Inc.

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/01/prweb12458024.htm

Risk-AI, LLC Aleksey Matiychenko +1 (646) 586-3124 Ext: 102

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Adobe’s Recent Options Activity Results

Updated Category News Views 114

Adobe's Options Activity Highlights In the world of finance, significant trades often signal important market sentiments. Recently, major investors have moved toward a bearish outlook on Adobe. Analyzing the options history for Adobe (NASDAQ: ADBE), we've identified a total of 67 significant trades. Our insights reveal that approximately 41% of these trades have been...

Continue Reading
Indonesia's Ongoing Challenge with Chinese Maritime Presence

Updated Category News Views 130

Indonesia's Maritime Security Efforts Intensify Recently, Indonesia's maritime security has been under increased scrutiny as incidents involving a Chinese coast guard vessel continue to escalate. This week, a Chinese vessel was driven from Indonesian waters not once, but twice, after interfering with a critical energy survey conducted by Pertamina, the state energy...

Continue Reading
Revolutionizing Game Development with Upheaval Games' Dreamer Portal

Updated Category News Views 140

Welcome to the Future of Game Development Upheaval Games, founded by veterans from the gaming industry, embraces a new frontier in game design with the introduction of The Dreamer Portal. This innovative web-based interface allows creators to effortlessly build immersive game content with just a simple prompt. Imagine the power of crafting unique creatures, items, and...

Continue Reading
Alvotech Moves Forward with Gobivaz® Approval in Europe

Updated Category News Views 190

Alvotech and Advanz Pharma Collaborate for Biosimilar Approval REYKJAVIK and LONDON – Alvotech (NASDAQ: ALVO), a renowned biotechnology firm, along with Advanz Pharma, a leading global pharmaceutical company, has shared important news regarding the marketing approval of Gobivaz®, a proposed biosimilar to Simponi® (golimumab). This biologic treatment is designed for...

Continue Reading
Exploring the Growth Potential of Remote Patient Monitoring Sector

Updated Category News Views 181

Remote Patient Monitoring Set for Dynamic Growth The increasing prevalence of chronic conditions worldwide is expected to significantly accelerate the growth of the remote patient monitoring (RPM) market. As conditions like hypertension, diabetes, and cardiovascular diseases become more common, coupled with an aging population, healthcare systems face immense pressure to...

Continue Reading